All Cases

Case Information

Theranos: How Did a $9 Billion Health Tech Startup End Up DOA?

Dal Bó, Ernesto , and Guo Xu
Publication date: 2/1/2021, pages 1-7

Stanford University drop-out Elizabeth Holmes hoped to disrupt the traditional $75 billion blood-testing business with only one drop from a finger prick instead of several vials of blood. The revolutionary claim of Theranos’ founder was that her groundbreaking technology enabled a full range of laboratory tests from a tiny sample. The Silicon Valley company, founded in 2003, assembled a powerful board and high-profile investors, becoming a media darling valued at $9 billion. By 2018, federal prosecutors filed criminal charges alleging Holmes had defrauded investors and mislead doctors and patients. The health technology company crashed from unicorn status leaving questions about what factors silenced doubters and enticed high-profile investors.
 
 



Educators may request a complimentary preview before purchasing. To find out more, please read about our publishing partnerships.

To request permission, please submit a Copyright Permission Request Form.

Berkeley Haas Case Series

A new collection of business case studies from Berkeley Haas

The aim of the Berkeley Haas Case Series is to incite business innovation by clarifying disruptive trends and questioning the status quo.

Learn more
Follow Us